BEAM · Beam Therapeutics Inc.
Market Cap
$3.04B
Shares
103.29M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$29.43
Open$28.82
Day$28.33–29.82
52W close$16.31–37.92
Avg vol 30d1.7M
Short int24.4M · 23.6% float · 16.1d
Short vol46%
Last earningsFeb 24, 2026
DataFeb 2020–Aug 2026
Filing10-Q · Aug 4
Up next
Next earnings call
Jun 15, 2027
Est · unconfirmed
· in 41 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 4, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.70
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+4%
above
Price vs 50-day avg
−1%
below
RSI (14)
53
neutral
MACD trend
Positive
52-week position
61%
mid-range
Momentum
relative strength
1-month return
+14%
trailing
6-month return
+13%
trailing
YTD return
+6%
this year
Relative strength
0%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $30 › 200d $28 — 50d above 200d
Institutional flow
Accumulating
+9% holders QoQ · +59 funds added
Insider flow
Distributing
Net -$10.0M over 90 days · 100% sells
Short interest
Rising
23.60% of float · ▲ +3.7% MoM · 16.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
278 holders — near 3-yr high, broad support
Squeeze score
79
high risk · 0–100
Fundamentals
Revenue growth
+33%
Y/Y
EPS growth
+82%
Y/Y
Free cash flow
$-360.0M
Quant / Vol
risk profile
Volatility
77%
annualized · 1-yr
Max drawdown
−38%
past year
ATR
5.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+4%
Bullish
Price vs 50-day avg
−1%
Neutral
RSI (14)
53
Neutral
MACD trend
Positive
Bullish
52-week position
61%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $30 › 200d $28 — 50d above 200d
Institutional flow
Accumulating
+9% holders QoQ · +59 funds added
Insider flow
Distributing
Net -$10.0M over 90 days · 100% sells
Short interest
Rising
23.60% of float · ▲ +3.7% MoM · 16.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
278 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $16
Now $29 · 61%
Range high $38
vs 200-day avg +4%
vs 50-day avg -1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BEAM
this stock
Beam Therapeutics Inc.
|
$3.04B | +6.2% | +33.3% | — | 23.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +20.1% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.77B | +3.5% | +20.8% | 19.7 | 2.3% |
|
ARGX
Argenx SE
|
$64.16B | +22.7% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.51B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BEAM | +3.9% | +13.6% | +12.9% | +15.3% | +6.2% |
| SPY | +0.5% | +1.2% | +13.3% | +2.7% | +12.5% |
| vs SPY | +3.4% | +12.4% | -0.4% | +12.6% | -6.3% |
Key facts
CIK
1745999
CUSIP
07373V105
13F (30d)
227 filings
219 filers
Visit website
Investor relations